Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13283000 | 0.85 | NPSR1 (0.44) | NPSR1RAB9AALDH1A1HTTLMNA | |
| SCHEMBL13282917 | 0.79 | RAB9A (0.43) | NPSR1RAB9AALDH1A1HTTLMNA | |
| SCHEMBL3378677 | 0.78 | PRKACA (0.40) | NPSR1RAB9ALMNAMEN1KMT2A | |
| SCHEMBL13282919 | 0.72 | NPSR1 (0.55) | NPSR1RAB9AALDH1A1HTTLMNA | |
| SCHEMBL3379725 | 0.71 | NPSR1 (0.57) | NPSR1RAB9AALDH1A1HTTLMNA | |
| SCHEMBL13102113 | 0.70 | ALDH1A1 (0.49) | NPSR1RAB9AALDH1A1HTTLMNA | |
| SCHEMBL13102104 | 0.69 | ALDH1A1 (0.49) | NPSR1RAB9AALDH1A1HTTLMNA | |
| SCHEMBL3378370 | 0.69 | NPSR1 (0.55) | NPSR1RAB9AALDH1A1HTTLMNA | |
| SCHEMBL13102244 | 0.69 | RORC (0.38) | NPSR1ALDH1A1HTTLMNAMEN1 | |
| SCHEMBL11051146 | 0.69 | SMN1; SMN2 (0.45) | NPSR1RAB9AALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585522-B1 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100190746-A1 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| EP-1585522-A4 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | ICAGEN INC (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1585522-A2 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040198724-A1 | Quinazolinones as potassium channel modulators | ICAGEN, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004058704-A2 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198724-A1 | Quinazolinones as potassium channel modulators | KCNQ1, KCNK17, KCNQ2 | NPSR1 1722/4885RAB9A 560/4885ALDH1A1 2776/4885 |
| US-20100190746-A1 | QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNK17, KCNQ2 | NPSR1 1722/4885RAB9A 560/4885ALDH1A1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.